Cabaletta Bio Inc - ESG Rating & Company Profile powered by AI
The webpage contains a zero-cost ESG assessment covering Cabaletta Bio Inc. Other companies in the rating industry group for Cabaletta Bio Inc are shown below. Full ESG assessment of Cabaletta Bio Inc can be accessed by signing up for free.
Cabaletta Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.8; made up of an environmental score of 8.0, social score of 4.0 and governance score of 8.0.
6.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 387 | Zim Laboratories Ltd | 6.9 | High |
| 387 | YungShin Global Holding Corp | 6.9 | High |
| 432 | Cabaletta Bio Inc | 6.8 | High |
| 432 | BLIS Technologies Ltd | 6.8 | High |
| 432 | Aileron Therapeutics Inc | 6.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cabaletta Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cabaletta Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Cabaletta Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cabaletta Bio Inc offer flexible work?
Sign up for free to unlockDoes Cabaletta Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cabaletta Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cabaletta Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose water use targets?
Sign up for free to unlockDoes Cabaletta Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cabaletta Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cabaletta Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cabaletta Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cabaletta Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cabaletta Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cabaletta Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Cabaletta Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Cabaletta Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cabaletta Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cabaletta Bio Inc
These potential risks are based on the size, segment and geographies of the company.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.